GENE THERAPY IN THALASSEMIA AND HEMOGLOBINOPATHIES

Laura Breda, Roberto Gambari, Stefano Rivella
  • Laura Breda
    Weill College Medical Center, Department of Pediatrics – Division of Hematology-Oncology, United States
  • Roberto Gambari
    Department of Biochemistry and Molecular Biology – Section of Molecular Biology, University of Ferrara, Italy
  • Stefano Rivella
    Weill College Medical Center, Department of Pediatrics – Division of Hematology-Oncology. NY.USA, | str2010@med.cornell.edu

Abstract

Sickle cell disease (SCD) and ß-thalassemia represent the most common hemoglobinopathies caused, respectively, by the alteration of structural features or deficient production of the ß-chain of the Hb molecule. Other hemoglobinopathies are characterized by different mutations in the α- or ß-globin genes and are associated with anemia and might require periodic or chronic blood transfusions. Therefore, ß-thalassemia, SCD and other hemoglobinopathies are excellent candidates for genetic approaches since they are monogenic disorders and, potentially, could be cured by introducing or correcting a single gene into the hematopoietic compartment or a single stem cell. Initial attempts at gene transfer of these hemoglobinopathies have proved unsuccessful due to limitations of available gene transfer vectors. With the advent of lentiviral vectors many of the initial limitations have been overcame. New approaches have also focused on targeting the specific mutation in the ß-globin genes, correcting the DNA sequence or manipulating the fate of RNA translation and splicing to restore ß-globin chain synthesis. These techniques have the potential to correct the defect into hematopoietic stem cells or be utilized to modify stem cells generated from patients affected by these disorders. This review discusses gene therapy strategies for the hemoglobinopathies, including the use of lentiviral vectors, generation of induced pluripotent stem cells (iPS) cells, gene targeting, splice-switching and stop codon readthrough.

 

Keywords

ß-thalassemia, sickle cell anemia, hemoglobinopathies, gene transfer, lentiviral vector, gene correction, splice-switching, stop codon readthrough, hematopoietic stem cells, induced pluripotent stem cells (iPS)

Full Text:

PDF
HTML
Submitted: 2014-06-11 11:31:33
Published: 2009-11-16 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
76

Views:
PDF
80
HTML
1783

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185